110,770 Shares in Integra LifeSciences Holdings Co. (NASDAQ:IART) Acquired by Woodline Partners LP

Woodline Partners LP purchased a new position in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 110,770 shares of the life sciences company's stock, valued at approximately $2,512,000. Woodline Partners LP owned 0.14% of Integra LifeSciences at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Quadrant Capital Group LLC raised its holdings in Integra LifeSciences by 5,960.9% during the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock worth $32,000 after purchasing an additional 1,371 shares in the last quarter. Sterling Capital Management LLC raised its stake in shares of Integra LifeSciences by 821.7% in the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock worth $49,000 after buying an additional 1,931 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Integra LifeSciences by 599.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after buying an additional 2,800 shares during the period. Covestor Ltd boosted its stake in Integra LifeSciences by 61.8% during the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock valued at $123,000 after buying an additional 2,071 shares in the last quarter. Finally, Empowered Funds LLC acquired a new position in Integra LifeSciences during the fourth quarter worth about $180,000. 84.78% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on IART shares. JPMorgan Chase & Co. cut their price target on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. JMP Securities decreased their price target on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a research report on Friday, May 9th. Truist Financial reduced their price objective on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Finally, Wells Fargo & Company decreased their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Four equities research analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $18.63.

Integra LifeSciences Stock Down 0.2%

NASDAQ:IART traded down $0.02 during trading hours on Thursday, hitting $12.68. 655,395 shares of the stock traded hands, compared to its average volume of 1,042,143. The firm has a market cap of $985.16 million, a price-to-earnings ratio of -140.84, a PEG ratio of 0.73 and a beta of 1.27. The firm has a 50 day moving average price of $16.43 and a 200 day moving average price of $21.11. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a fifty-two week low of $11.60 and a fifty-two week high of $32.66.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business had revenue of $382.65 million during the quarter, compared to analysts' expectations of $381.17 million. During the same period in the prior year, the company posted $0.55 earnings per share. The firm's revenue was up 3.7% on a year-over-year basis. Equities research analysts anticipate that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.